Carlumab  (Synonyms: CNTO 888)

Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CCL2/MCP1

Carlumab inhibits prostate tumor growth in mice and reduced macrophage infiltration (CD68) by decreasing tumor microvascular density^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6347  [NCBI]

P13500

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.87 kDa

915404-94-3

Liquid

Colorless to light yellow

[Carlumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized MCP-1/CCL2 Protein, Human (HY-P7237) can bind Carlumab. The EC₅₀ for this effect is 9.459 ng/mL.
• 
  Flow cytometric analysis of 1.5X10⁶ RAW264.7 cells treated with 100ng/mL LPS for 4 hours add 1μg/mL BFA for3 hours with Carlumab (HY-P99188, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control，cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Raghu G, et al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015;46(6):1740-1750.  [Content Brief]

  [2]. Pienta K J, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer[J]. Investigational new drugs, 2013, 31(3): 760-768.